Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma: Independence from other pretreatment characteristics

Cancer

Volumn 79, Issue 12, 1997, Pages 2402-2408

  Ennis, Ronald D ^a   Katz, Aaron E ^a   De Vries, Glen M ^a   Heitjan, Daniel F ^b   O'Toole, Kathleen M ^a   Rubin, Mark ^a   Buttyan, Ralph ^a   Benson, Mitchell C ^a   Schiff, Peter B ^a  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Polymerase chain reaction (PCR); Prostate adenocarcinoma; Prostate carcinoma; Reverse transcriptase polymerase chain reaction (RT PCR)

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; HUMANS; MALE; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RNA-DIRECTED DNA POLYMERASE;

EID: 0030939783     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970615)79:12<2402::AID-CNCR16>3.0.CO;2-V     Document Type: Article

References (31)

1. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6.
2. Hanks GE, Asbell S, Krall JM, Perez CA, Doggett S, Rubin P, et al. Outcome for lymph node dissection negative T-1b (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys 1991;21:1099-103.
3. Ennis RD, Peschel RE. Radiation therapy for prostate cancer: long-term results and implications for future advances. Cancer 1993;72:2644-50.
4. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy: influence of clinical stage and tumor grade. Urology 1993;41:207-16.
5. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
6. Ennis RD, Flynn SD, Fischer DB, Peschel RE. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implication for the choice of primary treatment. Int J Radiat Oncol Biol Phys 1994;30:317-22.
7. Catalona WJ, Smith DS. Five year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
8. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
9. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990;144:1180-4.
10. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcripatse-PCR assay. Urology 1994;43:765-75.
11. Katz AE, deVries GM, Begg MD, Raffo AJ, Cama C, O'Toole K, et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995;75:1642-8.
12. Zagars GK, Pollack A, Kavadi VS, vonEschenbach AC.Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
13. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate specific antigen driven outcome analysis. J Clin Oncol 1995;13:464-9.
14. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation rherapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
15. Zagars GK, Ayala AG, Eschenbach ACV, Pollack A. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1994;31: 237-45.
16. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
17. Bearhs OH, Henson DE, Hutter RVP, Myers MH. Manual for staging of cancer. 3rd edition. Philadelphia: J. B. Lippincott, 1988:177-82.
18. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, et al. Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology 1993;41:3-8.
19. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for staging of cancer. 4th edition. Philadelphia: J. B. Lipincott, 1992:181-6.
20. Oesterling JE, Movad MA, Wright GL, Beck GR. An analytical comparison of the three most commonly used prostate-specific antigen assays: tandem-R, tandem-E and IMx. Urology 1995;46:524-32.
21. Olsson CA, DeVries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996;155:1557-62.
22. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995;13:1195-200.
23. Jaakkola S, Voranen T, Leinonen I, Rannikko S, Stenman U-H. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. Clin Chem 1995;41:182-6.
24. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994;12:2634-9.
25. Wood DP, Banks ER, Humphereys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994;74:2533-40.
26. Wood DP, Weinstein M, Humpheries S, Rangnekar VM. Prognostic significance of circulating prostate cells. J Urol 1996;155(Suppl):418A.
27. Edelstein RA, Zietman AL, Morenas ADL, Krane RJ, Babayan RK, Dallow KC, et al. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996;47:370-5.
28. Smith MR, Biggar S, Hussain M. Prostate-specific antigen mssenger RNA is expressed in non-prostate cells: implications for the detection of micrometastases. Cancer Res 1995;55:2640-4.
29. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 1994;54:6344-7.
30. Clements J, Mukhtar A. Glandular kallikreins and prostate specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-9.
31. Sokoloff MH, Tso C-L, Kaboo R, Nelson S, Ko J, Dorey F, et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996;156:1560-6.